Prevalence and predictors of hospitalization in Crohn’s disease in a prospective population-based inception cohort from 2000-2012

Table 1 Demographic data and disease characteristics of the inception patients with Crohn’s disease n (%)

CD	n = 331
Males	176 (53.2)
Age at presentation (yr)	28; IQR 21-40
Follow-up (yr)	6; IQR: 2-9
Familial IBD	59 (17.8)
Location
L1	115 (34.7)
L2	105 (31.7)
L3	108 (32.6)
L4 only	4 (0.9)
Behavior at diagnosis
B1	182 (55.0)
B2	66 (19.9)
B3	83 (25.1)
Perianal disease	59 (17.8)
Arthritis	85 (25.7)
Ocular	12 (3.6)
Cutaneous	29 (8.8)
Steroid use	194 (58.6)
Azathioprine use	197 (59.5)
Biological use	27 (8.2)
Smoking habits at diagnosis
No	147 (44.4)
Ex	46 (13.9)
Yes	138 (41.7)

CD: Crohn’s disease.

Table 2 Predictive factors for immunosuppressive use and need for major inflammatory bowel diseases-related abdominal surgery

	Univariate analysis	Logistic regression
Immunosuppressive use
Early IBD-related hospitalization	P = 0.001, OR = 2.08	P = 0.01, OR = 2.03
	95%CI: 1.33-3.26	95%CI: 1.18-3.49
Perianal disease	P = 0.01, OR = 2.28	P = 0.046, OR = 2.07
	95%CI: 1.21-4.30	95%CI: 1.01-4.22
Age at diagnosis1	P < 0.001	P = 0.002
Location	P = 0.016 for location	NS
Smoking	P = 0.054	P = 0.06
Non-inflammatory behavior	P = 0.06	NS
Arthritis	P = 0.03, OR = 1.76	P < 0.001, OR = 2.96
	95%CI: 1.05-2.98	95%CI: 1.63-5.39
Steroid use (any time)	P < 0.001, OR = 5.78	-
	95%CI: 3.57-9.35
Major IBD-related abdominal surgery
Early IBD-related hospitalization	P < 0.001, OR = 7.24	P < 0.001, OR = 5.80
	95%CI: 4.34-12.1	95%CI: 3.20-10.5
Non-inflammatory behavior	P < 0.001, OR = 5.38	P < 0.001, OR = 2.15
	95%CI: 3.30-8.76	95%CI: 1.56-2.94
Location	P < 0.0012	P = 0.02 for location,
		P = 0.002, OR = 0.33
		95%CI: 0.16-0.67 for colonic location
Smoking	P = 0.17	NS
Perianal disease	P = 0.19	NS
Anaemia at presentation	P < 0.001, OR = 2.79	P < 0.001, OR = 4.39
	95%CI: 1.73-4.51	95%CI: 2.37-8.11

¹According to Montreal classification;

²If all locations were considered. NS: Non-significant.